Biotransformation Pathways and Metabolite Profiles of Oral [C]-Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors Authors: Sandeepraj Pusalkar,

Primary Laboratory of Origin: The study was conducted at a single clinical center in the United States: Comprehensive Clinical Development (Tacoma, Washington). Medical and clinical monitoring, including oversight of study drug packaging, labeling, and shipping, were conducted by the study sponsor: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (Cambridge, Massachusetts). Plasma and urine samples were shipped from Comprehensive Clinical Development to Frontage Laboratories, Inc. (Exton, Pennsylvania, USA), while fecal homogenates were prepared by Charles River Laboratories (Senneville, Québec City, Canada) and duplicate aliquots then shipped to Frontage Laboratories, Inc. for metabolite profiling. This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 7, 2020 as DOI: 10.1124/dmd.119.087338